Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985015736> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W1985015736 abstract "Purpose: Using current radiobiological models, we quantitatively examined the predicted clinical consequences of hypofractionation in prostate cancerradiotherapy while varying biological indices such as α/β, SF2, and total dose and dose per fraction. Method and Materials: Four hypofractionated treatment regimens, 22×2.94Gy, 16×3.63Gy, 12×4.3Gy, and 5×6.7Gy, were compared with standard fractionation of 39×2Gy. All regimens produce similar EQD2 to the tumor assuming α/β=2.4Gy for prostate carcinoma. Actual α/β values ranging from 1.5 to 8.5Gy for prostate carcinoma and fixed α/β values of 4Gy for both rectum and bladder were used to calculate biologically relevant parameters. The LQ model and gEUD formalism were used to transform the physical dose distribution into normalized equivalent uniform dose (gEUD2), from which TCP and NTCP were calculated. Final ranking of the radiotherapy plans was based on “complication‐free tumorcontrol probability”. Results: gEUD2 to rectum and bladder decreased by 28% and 23%, respectively, in the 6.7Gy/fraction regimen compared with 2Gy/fraction using “a”=5 for the gEUD calculation. A corresponding 10% decrease in NTCP was predicted for the 6.7Gy/fraction regimen compared with 2Gy/fraction. Conversely, predicted TCP for hypofractionated regimens decreases significantly with increasing SF2 and α/β. We found that for relatively responsive tumor cells (SF2=0.4–0.5), complication‐free tumorcontrol probability was superior for nearly all hypofractionated regimens even for α/β values up to 8.5Gy. For less responsive tumor cells, (SF2=0.6), 6.7Gy/fx is predicted to be inferior to standard fractionation even when α/β=1.7Gy, and the other hypofractionation regimens remain superior to the standard fractionation for α/β values up to 3.5Gy. Conclusion: Existing radiobiological data and models predict better clinical results from hypofractionation than standard fractionation for prostate carcinoma when SF2<0.5 and <5×106 clonogenic cells, implying that it is superior for early stage disease. This is true even when tumor α/β is high. Part funded by Varian Medical Systems." @default.
- W1985015736 created "2016-06-24" @default.
- W1985015736 creator A5004147761 @default.
- W1985015736 creator A5004318479 @default.
- W1985015736 creator A5022615064 @default.
- W1985015736 creator A5068196186 @default.
- W1985015736 date "2008-06-01" @default.
- W1985015736 modified "2023-09-25" @default.
- W1985015736 title "TU-EE-A2-05: Hypofractionation: What Does It Mean For Prostate Cancer Treatment?" @default.
- W1985015736 doi "https://doi.org/10.1118/1.2962615" @default.
- W1985015736 hasPublicationYear "2008" @default.
- W1985015736 type Work @default.
- W1985015736 sameAs 1985015736 @default.
- W1985015736 citedByCount "0" @default.
- W1985015736 crossrefType "journal-article" @default.
- W1985015736 hasAuthorship W1985015736A5004147761 @default.
- W1985015736 hasAuthorship W1985015736A5004318479 @default.
- W1985015736 hasAuthorship W1985015736A5022615064 @default.
- W1985015736 hasAuthorship W1985015736A5068196186 @default.
- W1985015736 hasConcept C121608353 @default.
- W1985015736 hasConcept C126322002 @default.
- W1985015736 hasConcept C126894567 @default.
- W1985015736 hasConcept C2776235491 @default.
- W1985015736 hasConcept C2780192828 @default.
- W1985015736 hasConcept C2781074409 @default.
- W1985015736 hasConcept C2781413609 @default.
- W1985015736 hasConcept C2989005 @default.
- W1985015736 hasConcept C71924100 @default.
- W1985015736 hasConcept C81182388 @default.
- W1985015736 hasConceptScore W1985015736C121608353 @default.
- W1985015736 hasConceptScore W1985015736C126322002 @default.
- W1985015736 hasConceptScore W1985015736C126894567 @default.
- W1985015736 hasConceptScore W1985015736C2776235491 @default.
- W1985015736 hasConceptScore W1985015736C2780192828 @default.
- W1985015736 hasConceptScore W1985015736C2781074409 @default.
- W1985015736 hasConceptScore W1985015736C2781413609 @default.
- W1985015736 hasConceptScore W1985015736C2989005 @default.
- W1985015736 hasConceptScore W1985015736C71924100 @default.
- W1985015736 hasConceptScore W1985015736C81182388 @default.
- W1985015736 hasLocation W19850157361 @default.
- W1985015736 hasOpenAccess W1985015736 @default.
- W1985015736 hasPrimaryLocation W19850157361 @default.
- W1985015736 hasRelatedWork W1560439870 @default.
- W1985015736 hasRelatedWork W1622777584 @default.
- W1985015736 hasRelatedWork W1781674450 @default.
- W1985015736 hasRelatedWork W1973538442 @default.
- W1985015736 hasRelatedWork W1990524522 @default.
- W1985015736 hasRelatedWork W1997923429 @default.
- W1985015736 hasRelatedWork W1999207872 @default.
- W1985015736 hasRelatedWork W2009771433 @default.
- W1985015736 hasRelatedWork W2051563205 @default.
- W1985015736 hasRelatedWork W2085066133 @default.
- W1985015736 hasRelatedWork W2109782006 @default.
- W1985015736 hasRelatedWork W2128499940 @default.
- W1985015736 hasRelatedWork W2130514725 @default.
- W1985015736 hasRelatedWork W2135238404 @default.
- W1985015736 hasRelatedWork W2141944007 @default.
- W1985015736 hasRelatedWork W2148117492 @default.
- W1985015736 hasRelatedWork W2154737394 @default.
- W1985015736 hasRelatedWork W2514401922 @default.
- W1985015736 hasRelatedWork W3002858853 @default.
- W1985015736 hasRelatedWork W56623410 @default.
- W1985015736 isParatext "false" @default.
- W1985015736 isRetracted "false" @default.
- W1985015736 magId "1985015736" @default.
- W1985015736 workType "article" @default.